TrialBMC cancer2024

SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.

Elisha Fredman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.